Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.

被引：0
|
作者：
Lee, Choong-kun
Jung, Minkyu
Park, Sejung
Kwon, Woo Sun
Kim, Kyoo Hyun
Hong, Moonki
Kim, Hyunwook
Kim, Hyo Song
Chung, Hyun Cheol Cheol
Rha, Sun Young
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Yonsei Canc Ctr, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Songdang Inst Canc Res, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
374
引用
收藏
页码：374 / 374
页数：1
相关论文
共 50 条
  • [21] A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer
    Hironaka, Shuichi
    Kadowaki, Shigenori
    Izawa, Naoki
    Nishina, Tomohiro
    Yamanaka, Takeharu
    Minashi, Keiko
    Muro, Kei
    Sunakawa, Yu
    Kajiwara, Takeshi
    Hayashi, Yuichiro
    Kawakami, Yutaka
    Nakajima, Takako Eguchi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [22] Nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Preliminary results from an open-label, single-arm, phase 2 study
    Jiang, Zhichao
    Zhang, Wen
    Yang, Lin
    Sun, Yongkun
    Zhao, Yun-Bo
    Deng, Wei
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 332 - 332
  • [24] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
    Cohn, Allen L.
    Shumaker, Grace C.
    Khandelwal, Pankaj
    Smith, David A.
    Neubauer, Marcus A.
    Mehta, Nilesh
    Richards, Donald
    Watkins, David L.
    Zhang, Kathy
    Yassine, Mohamed R.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177
  • [25] PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study
    Miaomiao Gou
    Yong Zhang
    Zhikuan Wang
    Niansong Qian
    Guanghai Dai
    Investigational New Drugs, 2024, 42 : 171 - 178
  • [26] Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
    Meng, Xiangrui
    Wu, Tao
    Hong, Yonggui
    Fan, Qingxia
    Ren, Zhonghai
    Guo, Yanzhen
    Yang, Xiuli
    Shi, Pei
    Yang, Jiamei
    Yin, Xianzhe
    Luo, Zhiquan
    Xia, Jin
    Zhou, Yue
    Xu, Mengli
    Liu, Enjie
    Jiang, Guozhong
    Li, Shenglei
    Zhao, Feng
    Ma, Chi
    Ma, Chuanxiang
    Hou, Zhiguo
    Li, Jing
    Wang, Junsheng
    Wang, Feng
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 245 - 253
  • [27] PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study
    Gou, Miaomiao
    Zhang, Yong
    Wang, Zhikuan
    Qian, Niansong
    Dai, Guanghai
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 171 - 178
  • [28] A phase II single-center single-arm study of PD-1 inhibitor in combination with albumin paclitaxel and apatinib as second-line treatment of metastatic gastric cancer (mGC).
    Gou, Miaomiao
    Qian, Niansong
    Wang, Zhikuan
    Yan, Huan
    Zhang, Yong
    Si, Haiyan
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16024 - E16024
  • [29] Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial
    Wei, Jing
    Zhang, Pengfei
    Hu, Qiancheng
    Cheng, Xiaolong
    Shen, Chaoyong
    Chen, Zhixin
    Zhuang, Wen
    Yin, Yuan
    Zhang, Bo
    Gou, Hongfeng
    Yang, Kun
    Bi, Feng
    Liu, Ming
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [30] Phase II Study of Weekly Paclitaxel as a Second-line Treatment for S-1-refractory Advanced Gastric Cancer
    Matsuda, Goro
    Kunisaki, Chikara
    Makino, Hirochika
    Fukahori, Michiko
    Kimura, Jun
    Sato, Tsutomu
    Oshima, Takashi
    Nagano, Yasuhiko
    Fuii, Shoichi
    Takagawa, Ryo
    Kosaka, Takashi
    Ono, Hedetaka A.
    Akiyama, Hirotoshi
    Ichikawa, Yasushi
    ANTICANCER RESEARCH, 2009, 29 (07) : 2863 - 2867
12345